Empasiprubart
Based on 1 Customer Validation
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: ≥99.0%
- CAS No.: 2579031-19-7
- Masse moléculaire:145.74 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
Complement C2
Empasiprubar prevents complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection in an in vitro model[1]. Empasiprubar can inhibit C4 downstream complement activation induced by anti-GM1 antibody binding to motor neurons (MN) derived from induced pluripotent stem cells (iPSC) model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys[1].
-
Dosage:0.5-30 mg/kg
-
Administration:Intravenous injection (i.v.); once daily; 60 days
-
Result:Reduced free C2 levels and classical pathway activity.
-
Animal Model:Schwann cell nodal membrane injury mice model[2].
-
Dosage:200 mg/kg
-
Administration:Intravenous injection (i.v.); once
-
Result:Attenuated injury to paranodal proteins at the node of Ranvier and improves respiratory function in vivo Schwann cell nodal membrane injury models.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized C2/Complement C2 Protein, Human (HEK293, His, HY-P74375) can bind Empasiprubart. The EC50 for this effect is 8.454 ng/mL.
Chemical Information
-
CAS No. 2579031-19-7
-
Appearance Liquid
-
Masse moléculaire 145.74 kDa
-
Color Colorless to light yellow
-
SMILES
[Empasiprubart]
-
Synonyms
ARGX-117
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Van de Walle I, et al. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol. 2021 Apr;147(4):1420-1429.e7. [Content Brief]
[2]. Campbell CI, et al. Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model. Brain Commun. 2022 Nov 23;4(6):fcac306. [Content Brief]
[3]. Budding K, et al. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 10;9(1):e1107. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Empasiprubart Related Classifications
HY-P990025 Related Classifications
Powered by Bioz